GLP-1 receptor agonists like semaglutide and tirzepatide are effective and increasingly safe for older adults with obesity, reducing cardiometabolic events while maintaining muscle mass — challenging the traditional reluctance to treat obesity in the elderly.
Muscle mass maintainedGLP-1 receptor agonists enhance weight loss and reduce cardiometabolic events in older adults while maintaining muscle mass — the key safety concern in elderly obesity treatment
What the researchers found
The review identifies several key findings regarding obesity pharmacotherapy in adults over 60:
• Nine anti-obesity medications are currently approved, but clinical trial evidence in older adults is predominantly limited to incretin-based therapies: liraglutide, semaglutide, and tirzepatide
• GLP-1 receptor agonists enhance weight loss and reduce cardiometabolic events in older populations
• Critically, these drugs help maintain muscle mass during weight loss — addressing the primary safety concern in elderly obesity treatment
• Recent evidence supports that intentional weight loss in older adults with overweight/obesity is effective and safe, reducing the historical reluctance to prescribe anti-obesity medications
• Lifestyle interventions with emphasis on resistance training remain the foundation, with pharmacotherapy as an adjunct for refractory cases
Why it matters
The global elderly population is growing rapidly, and obesity rates in this group are rising in parallel. Untreated obesity in older adults accelerates functional decline, worsens cognition, and reduces quality of life on top of standard cardiometabolic risks. Establishing that GLP-1 peptide drugs are safe and effective in this population — without excessive muscle loss — could transform geriatric obesity management and improve millions of lives.
How the study worked
Narrative review of evidence on anti-obesity medications in adults over 60 years, drawing from clinical trial data, cardiometabolic outcome studies, and body composition analyses. The review focuses on incretin-based therapies as the primary evidence base for this age group.
What this study cannot tell us
Narrative review methodology without systematic search or quality assessment. Most evidence for older adults comes from subgroup analyses of larger trials rather than dedicated elderly-focused studies. Long-term data on body composition changes and functional outcomes in older adults taking GLP-1 agonists are limited. The review acknowledges that future RCTs specifically designed for older adults are needed.
How to read the evidence
This is a narrative review synthesizing available evidence from clinical trials, predominantly subgroup data from large GLP-1 agonist trials. While it provides a comprehensive clinical overview, it does not use systematic review methodology. The underlying evidence for GLP-1 agonists in general is strong (large RCTs), but elderly-specific data remain limited.
When this study was published
Published in 2025, this review is current and addresses a timely topic as GLP-1 prescribing rapidly expands into older adult populations. The call for elderly-specific RCTs reflects an active evidence gap.
The bigger picture
The obesity treatment paradigm is shifting from 'weight loss at any cost' to 'healthy weight loss that preserves function.' This is especially important in older adults where sarcopenic obesity (too much fat, too little muscle) is common. GLP-1 agonists appear uniquely suited to this population because they promote fat loss while relatively sparing lean mass. As the GLP-1 revolution reaches geriatric medicine, evidence-based guidelines for older adults will become essential.
Questions still open
- Do GLP-1 agonists combined with resistance exercise produce better muscle preservation than either intervention alone in older adults?
- At what age does the risk-benefit calculation of obesity pharmacotherapy shift, and should there be upper age limits for treatment?
- How do the newer dual and triple agonists (tirzepatide, retatrutide) compare to single GLP-1 agonists for body composition in elderly patients?
Common questions
Is it safe for older adults to take GLP-1 drugs for weight loss?
What is the 'obesity paradox' in older adults?
Read the original research
Obesity pharmacotherapy in older adults: a narrative review of evidence.
International journal of obesity (2005), 49(3), 369-380
Citation
Henney, Alex E; Wilding, John P H; Alam, Uazman; Cuthbertson, Daniel J. (2025). Obesity pharmacotherapy in older adults: a narrative review of evidence.. International journal of obesity (2005), 49(3), 369-380. https://doi.org/10.1038/s41366-024-01529-z